John Welch
Family Medicine · Terre Haute, INNPI 1528178886
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 156 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,326 and has fallen 98.7% since, to $18 in 2023.
Across 156 payments — averaging $14.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$299
- Novo Nordisk$289
- AbbVie$225
- Lilly USA, LLC$185
- Novartis$177
- GSK$153
- plus $971 from 21 others
What the payments were for
- Food & beverage$2,25998%
- Education$402%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 16 | $299 |
| Novo Nordisk | 27 | $289 |
| AbbVie(2 entities) | 13 | $225 |
| Lilly USA, LLC | 15 | $185 |
| Novartis | 12 | $177 |
| GSK | 16 | $153 |
| AstraZeneca | 5 | $148 |
| E.r. Squibb & Sons, L.L.C. | 6 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $113 |
| Astellas Pharma US Inc | 5 | $101 |
| Pfizer | 6 | $77 |
| Amarin Pharma, Inc. | 5 | $76 |
| Boehringer Ingelheim | 5 | $73 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Abbott | 2 | $31 |
| Johnson & Johnson | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Neos Therapeutics, LP | 1 | $19 |
| Radius Health, Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Merck | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Grifols USA, LLC | 1 | $11 |
How this compares
$2,299 in reported general payments places this provider in the 75th percentile of 2,709 family medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lamotrigine | 19 | $699 |
| Metoprolol Succinate | 12 | $342 |
| Losartan Potassium | 13 | $301 |
| Furosemide | 13 | $72 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Terre Haute
- Richard TannerIndianapolis$1.6M
- James AndryBloomington$715K
- Richard FeldmanIndianapolis$476K
- Anthony InzerelloEvansville$308K
- Joe BanksIndianapolis$294K
- Steven GatewoodElwood$281K
- Shekar PushpalaCarmel$239K
- Victoria MoyerKokomo$188K
- Thomas KintanarFort Wayne$185K
- Jeffrey HiltzMuncie$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.